Evidence map›Paper›PMID 34843671›Full record

ArticleThe Lancet. Global health2022

Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study.

Anuja P Premawardhena, Dileepa Senajith Ediriweera, Amir Sabouhanian, Angela Allen, David Rees, Shanthimala de Silva, Windsor Perera, Nimal Katugaha, Mahinda Arambepola, Robert C Yamashita and 14 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 6 countries.

Anuja P PremawardhenaDepartment of Medicine, Faculty of Medicine, University of Kelaniya, Sri Lanka.
Dileepa Senajith EdiriweeraHealth Data Science Unit, Faculty of Medicine, University of Kelaniya, Sri Lanka.
Amir SabouhanianFaculty of Medicine, University of Toronto, Toronto, ON, Canada.
Angela AllenDepartment of Molecular Haematology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
David ReesDepartment of Paediatric Haematology, King's College London, London, UK.
Shanthimala de SilvaAsiri Hospital, Colombo, Sri Lanka.
Windsor PereraTeaching Hospital Kurunegala, Kurunegala, Sri Lanka.
Nimal KatugahaTeaching Hospital Kurunegala, Kurunegala, Sri Lanka.
Mahinda ArambepolaDepartment of Paediatrics, National Teaching Hospital, Kandy, Sri Lanka.
Robert C YamashitaDepartment of Hematology, University of California, San Francisco, CA, USA; Department of Liberal Studies, California State University, San Marcos, CA, USA.
Sachith MettanandaDepartment of Paediatrics, Faculty of Medicine, University of Kelaniya, Sri Lanka.
Nilam JiffrySirimavo Bandaranayake Specialized Children's Hospital, Peradeniya, Sri Lanka.
Vikita MehtaMcMaster University, Hamilton, ON, Canada.
Refai CaderPolicy Analysis and Development Ministry of Health Sri Lanka, Colombo, Sri Lanka.
Dayananda BandaraTeaching Hospital Kurunegala, Kurunegala, Sri Lanka.
Timothy St PierreDepartment of Physics, School of Physics, Mathematics, and Computing, University of Western Australia, Crawley, WA, Australia.
Giulia MuracaClinical Epidemiology Unit, Department of Medicine, Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Christopher FisherDepartment of Molecular Haematology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK.
Abirami KirubarajanFaculty of Medicine, University of Toronto, Toronto, ON, Canada.
Shawn KhanFaculty of Medicine, University of Toronto, Toronto, ON, Canada.
Stephen AllenDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Sanath P LamabadusuriyaFaculty of Medicine, University of Colombo, Colombo, Sri Lanka.
David J WeatherallDepartment of Molecular Haematology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK.
Nancy F OlivieriPediatrics, Medicine, and Public Health Sciences, University of Toronto, Toronto, ON, Canada. Electronic address: nancy@hemoglobal.org.
University of Toronto · CAUniversity of Kelaniya · LKMRC Weatherall Institute of Molecular Medicine · GBJohn Radcliffe Hospital · GBKarolinska Institutet · SEKing's College London · GBLanka Hospitals · LKLiverpool School of Tropical Medicine · GBMcMaster University · CATeaching Hospital Kandy · LKUniversity of California, San Francisco · USUniversity of Colombo · LKUniversity of Western Australia · AU

Funding

Medical Research Council
6 · The paper itself

Abstract

backgroundWorldwide, haemoglobin E β-thalassaemia is the most common genotype of severe β-thalassaemia. The paucity of long-term data for this form of thalassaemia makes evidence-based management challenging. We did a long-term observational study to define factors associated with survival and complications in patients with haemoglobin E thalassaemia.

methodsIn this prospective, longitudinal cohort study, we included all patients with haemoglobin E thalassaemia who attended the National Thalassaemia Centre in Kurunegala, Sri Lanka, between Jan 1, 1997, and Dec 31, 2001. Patients were assessed up to three times a year. Approaches to blood transfusions, splenectomy, and chelation therapy shifted during this period. Survival rates between groups were evaluated using Kaplan-Meier survival function estimate curves and Cox proportional hazards models were used to identify risk factors for mortality.

findings109 patients (54 [50%] male; 55 [50%] female) were recruited and followed up for a median of 18 years (IQR 14-20). Median age at recruitment was 13 years (range 8-21). 32 (29%) patients died during follow-up. Median survival in all patients was 49 years (95% CI 45-not reached). Median survival was worse among male patients (hazard ratio [HR] 2·51, 95% CI 1·16-5·43), patients with a history of serious infections (adjusted HR 8·49, 2·90-24·84), and those with higher estimated body iron burdens as estimated by serum ferritin concentration (adjusted HR 1·03, 1·01-1·06 per 100 units). Splenectomy, while not associated with statistically significant increases in the risks of death or serious infections, ultimately did not eliminate a requirement for scheduled transfusions in 42 (58%) of 73 patients. Haemoglobin concentration less than or equal to 4·5 g/dL (vs concentration >4·5 g/dL), serum ferritin concentration more than 1300 μg/L (vs concentration ≤1300 μg/L), and liver iron concentration more than 5 mg/g dry weight of liver (vs concentration ≤5 mg/g) were associated with poorer survival.

interpretationPatients with haemoglobin E thalassaemia often had complications and shortened survival compared with that reported in high-resource countries for thalassaemia major and for thalassaemia intermedia not involving an allele for haemoglobin E. Approaches to management in this disorder remain uncertain and prospective studies should evaluate if altered transfusion regimens, with improved control of body iron, can improve survival.

fundingWellcome Trust, Medical Research Council, US March of Dimes, Anthony Cerami and Ann Dunne Foundation for World Health, and Hemoglobal.

Indexed as

AdolescentAdultbeta-ThalassemiaBlood TransfusionChelation TherapyChildFemaleFerritinsHemoglobin EHemoglobinsHumansKaplan-Meier EstimateLongitudinal StudiesMaleMiddle AgedProportional Hazards ModelsFerritinsHemoglobin EHemoglobins

Identifiers

PMID34843671
PMCPMC8672061
OpenAlexW3215335147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.